Effects of mitoxantrone on action potential and membrane currents in isolated cardiac myocytes

British Journal of Pharmacology

Volumn 127, Issue 2, 1999, Pages 321-330

  Wang, Ge Xin ^a   Zhou, Xiao Bo ^a   Eschenhagen, Thomas ^a   Korth, Michael ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Action potential; Atrial myocytes; Cardiac effects; Early afterdepolarization; Membrane currents; Mitoxantrone; Muscarinic receptors; Ventricular myocytes

Indexed keywords

CALCIUM ION; CARBACHOL; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); ISOPRENALINE; MITOXANTRONE; MUSCARINIC RECEPTOR; PHENYLISOPROPYLADENOSINE; POTASSIUM ION; TETRODOTOXIN;

ACTION POTENTIAL; ANIMAL CELL; ARTICLE; CALCIUM CURRENT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GUINEA PIG; HEART DEPOLARIZATION; HEART MUSCLE CELL; MALE; MEMBRANE CURRENT; NONHUMAN; PATCH CLAMP; POTASSIUM CURRENT; PRIORITY JOURNAL;

ACTION POTENTIALS; ANIMALS; ANTINEOPLASTIC AGENTS; CARBACHOL; FEMALE; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); GUINEA PIGS; HEART; HEART VENTRICLES; HUMANS; MALE; MEMBRANE POTENTIALS; MITOXANTRONE; MUSCARINIC AGONISTS; MUSCARINIC ANTAGONISTS; MYOCARDIUM; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS; QUINUCLIDINYL BENZILATE; RADIOLIGAND ASSAY; RATS; RECEPTORS, MUSCARINIC; TETRODOTOXIN;

EID: 0033026382     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702547     Document Type: Article

References (50)

1. Abi-Gerges, N., Eschenhagen, T., Hove-Madsen, L., Fischmeister, R. & Mery, P.-F. (1997). Methylene blue is a muscarinic antagonist in cardiac myocytes. Mol. Pharmacol., 52, 482-490.
2. Alderton, P.M., Gross, J. & Green, M.D. (1992). Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in chronic cardiotoxicity animal model. Cancer Res., 52, 194-201.
3. Attwell, D., Cohen, I. & Eisner, D. (1981). The effects of heart rate on the action potential of guinea-pig and human ventricular muscle. J. Physiol. (Lond.), 313, 439-461.
4. Backx, P.H. & Marban, E. (1993). Background potassium current active during the plateau of the action potential in guinea pig ventricular myocytes. Circ. Res., 72, 890-900.
5. Belardinelli, L., Linden, J. & Berne, R.M. (1989). The carciac effects of adenosine. Prog. Cardiovasc. Dis., 32, 73-97.
6. Benjamin, R.S. (1995). Rationale for the use of mitoxantrone in the older patient: cardiac toxicity. Semin. Oncol., 22, 11-13.
7. Ks) in human and guinea pig ventricle. J. Am. Coll. Cardiol., 29 (suppl A), 512A (abstract).
8. Breitwieser, G.E. & Szabo, G. (1985). Uncoupling of cardiac muscarinic and β-adrenergic receptors from ion channels by a guanine nucleotide analogue. Nature, 317, 538-450.
9. sK channels by the chromanol 293B. Pflügers Arch., 432, 1094-1096.
10. Dodd, D.A., Atkinson, J.B., Olson, R.D., Buck, S., Cusack, B.J., Fleischer, S. & Boucek, R.J. (1993). Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in a chronic rabbit model. J. Clin. Invest., 91, 1697-1705.
11. Dorr, R.T., Ship, N.G. & Lee, K.M. (1991). Comparison of cytotoxicity in heart cells and tumor cells exposed to DNA intercalating agents in vitro. Anti-Cancer Drugs, 2, 27-33.
12. + dependence. J. Physiol. (Lond.), 435, 395-420.
13. Faulds, D., Balfour, J.A., Chrisp, P. & Langtry, H.D. (1991). Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs, 41, 400-449.
14. Gams, R.A. & Wesler, M.J. (1984). Mitoxantrone cardiotoxicity: results from Southeastern Cancer Study Group. Cancer Treat. Symp., 3, 31-33.
15. Gjini, V., Korth, M., Schreieck, J., Weyerbrock, S., Schömig, A. & Schmitt, C. (1996). Differential class III antiarrhythmic effects of ambasilide and dofetilide at different extracellular potassium and pacing frequencies. J. Cardiovasc. Pharmacol., 28, 314-320.
16. Gwilt, M., Arrowsmith, J.E., Blackburn, K.J., Burges, R.A., Cross, P.E., Dalrymple, H.W. & Higgins, A.J. (1991). UK-68,798: A novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. J. Pharmacol. Exp. Ther., 256, 318-324.
17. Hamill, O.P., Marty, A., Neher, E., Sakmann, B. & Sigworth, F.J. (1981). Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflügers Arch., 391, 85-100.
18. Ks in guinea-pig isolated ventricular myocytes. Exp. Physiol., 81, 587-603.
19. Henderson, I.C., Allegra, J.C., Woodcock, T., Wolff, S., Bryan, S., Cartwright, K., Dukart, G. & Henry, D. (1989). Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J. Clin. Oncol., 7, 560-571.
20. Herman, E.H., Zhang, J., Hasinoff, B.B., Clark, J.R. & Ferrans, V.J. (1997). Comparison of the structural changes induced by doxorubicin and mitoxantrone in the heart, kidney and intestine and characterization of the Fe (III)-mitoxantrone complex. J. Mol. Cell. Cardiol., 29, 2415-2430.
21. + channels by intracellular factors. In Potassium channels in normal and pathological conditions. eds. Vereecke, J., van Bogaert, P., Verdonck, F. pp. 103-117. Leuven: Leuven University Press.
22. Hondeghem, I., & Snyders, D. (1990). Class III antiarrhythmic agents have a lot of potential but a long way to go: reduced effectiveness and dangers of reverse use dependence. Circulation, 81, 686-690.
23. Johnson, R.K., Zee-Cheng, R.K.-Y., Lee., W.W., Acton, E.M., Henry, D.W. & Cheng, C.C. (1979). Experimental antitumor activity of aminoanthraquinones. Cancer Treat. Rep., 63, 425-439.
24. Josephson, I.R., Sanchez-Chapula, J. & Brown, A.M. (1984). Early outward current in rat single ventricular cells. Circ. Res., 54, 157-162.
25. + current by dofetilide. Circ. Res., 72, 75-83.
26. kr. Circulation, 94, 2938-2946.
27. Katritsis, D. & Camm, A.J. (1993). New class III antiarrhythmic drugs. Eur. Heart J., 14, 93-99.
28. Kiyosue, T. & Arita, M. (1989). Late sodium current and its contribution to action potential configuration in guinea pig ventricular myocytes. Circ. Res., 64, 389-397.
29. + channels by adenosine in isolated atrial cells: involvement of GTP-binding proteins. Pflügers Arch., 407, 264-274.
30. + channel current in isolated atrial myocytes and possible role of GTP-binding proteins. Pflügers Arch., 410, 227-233.
31. Murdock, K.C., Child, R.G., Fabio, P.F., Angier, R.B., Wallace, R.E., Durr, F.E. & Citarella, R.V. (1979). Antitumor agents. I. 1,4-bis[(aminoalkyl)amino]-9,10-anthracenediones. J. Med. Chem., 22, 1024-1030.
32. Peaffinger, P.J., Martin, J.M., Hunter, D.D., Nathanson, N.M. & Hille, B. (1985). GTP-binding proteins couple cardiac muscarinic receptors to a K channel. Nature, 317, 536-538.
33. Posner, L.E., Dukart, G., Goldberg, J., Bernstein, T. & Cartwright, K. (1985). Mitoxantrone: an overview of safety and toxicity. Invest. New Drugs, 3, 123-132.
34. Powell, T., Terrar, D.A. & Twist, V.W. (1980). Electrical properties of individual cells isolated from adult rat ventricular myocardium. J. Physiol. (Lond.). 302, 131-153.
35. Ks in guinea pig ventricular myocytes. Circulation, 94 (suppl I), I-529 (abstract).
36. +- current: differential sensitivity to block by class III antiarrhythmic agents. J. Gen. Physiol., 96, 195-215.
37. K and screens membrane surface charge in cardiac cells. Am. J. Physiol., 259, H1881 - H1889.
38. Sanguinetti, M.C. & Salata, J.J. (1996). Cardiac potassium channel modulators: potential for antiarrhythmic therapy. In Potassium channels and their modulators. eds. Evans, J.M., Hamilton, T.C., Longman, S.D. & Stemp, G. pp. 221-256. London: Taylor & Francis Ltd.
39. Schreieck, J., Wang, Y., Gjini, V., Korth, M., Zrenner, B., Schömig, A. & Schmitt, C. (1977). Differential effect of β-adrenergic stimulation on the frequency-dependent electrophysiologic actions of the new class III antiarrhythmics dofetilide, ambasilide and chromanol 293B. J. Cardiovasc. Electrophysiol., 8, 1420-1430.
40. Shenkenberg, T.D. & Von Hoff, D.D. (1986). Mitoxantrone: a new anticancer drug with significant clinical activity. Ann. Intern. Med., 105, 67-81.
41. Shibasaki, T. (1987). Conductance and kinetics of delayed rectifier potassium channels in nodal cells of the rabbit heart. J. Physiol. (Lond.), 387, 227-250.
42. Shimoni, Y., Clark, R.B. & Giles, W.R. (1992). Role of inwardly rectifying potassium current in rabbit ventricular action potential. J. Physiol. (Lond.), 448, 709-728.
43. Kr channel. J. Gen. Physiol., 107, 611-619.
44. K blocking drug, UK-68,798: potent in guinea pig but no effect in rat myocardium. J. Cardiovasc. Pharmacol., 16, 401-410.
45. Unverferth, D.V., Unverferth, B.J., Balcerzak, S.P., Bashore, T.A. & Neidhart, J.A. (1983). Cardiac evaluation of mitoxantrone. Cancer Treat. Rep., 67, 343-350.
46. Weiss, R.B. (1989). Mitoxantrone: its development and role in clinical practice. Oncology, 3, 135-147.
47. Wiseman, L.R. & Spencer, C.M. (1997). Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer. Drugs & Aging. 10, 473-485.
48. Kr: implications for torsades de pointes and reverse use-dependence. Circulation, 93, 407-411.
49. + current in cardiac cells. Circ. Res., 80, 782-789.
50. Zeng, J., Laurita, K.R., Rosenbaum, D.S. & Rudy, Y. (1995). Two components of the delayed rectifier K current in ventricular myocytes of the guinea pig type: theoretical formulation and their role in repolarization. Circ. Res., 77, 140-152.